ClinicalTrials.gg
Not yet recruitingNCT07654517Updated Nov 4, 2026

Pirfenidone for Idiopathic Subglottic Stenosis: A Pilot Trial of Tolerability and Feasibility

A Phase 1 interventional study of Pirfenidone and Placebo in Idiopathic Subglottic Stenosis and Subglottic Stenosis (SGS), sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's. Not yet recruiting at 2 sites in Canada. Open to female participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-04.

Sponsored by London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's · Phase 1, Interventional, and Treatment

How we know

Updated Nov 4, 2026Start date movedPrimary completion moved+9 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Female
01

Study summary

Idiopathic subglottic stenosis (iSGS) is a rare condition where scar tissue forms just below the vocal cords and in the upper windpipe, making the airway narrow. People with iSGS often feel short of breath, hear noisy breathing, and notice changes in their voice. Many need repeated operations and steroid injections to open the airway, but the narrowing usually comes back, so these treatments are not a cure.

Recent research from a Canadian iSGS registry and biobank has shown that this disease is driven by overactive scarring pathways, similar to those seen in idiopathic pulmonary fibrosis (IPF), a serious lung disease. Pirfenidone is an oral medication already approved for IPF that works by slowing down the cells and signals that cause scarring. Because the same scarring pathways appear to be active in iSGS, pirfenidone may be able to slow or reduce the build-up of scar tissue in the airway.

In this study, adults with iSGS will be randomly assigned (like flipping a coin) to receive either pirfenidone or a placebo (a look-alike pill with no active drug) for 52 weeks, in addition to their usual intralesional steroid injections. The pirfenidone dose will be increased gradually over the first two weeks up to a regular dose taken three times a day with food, which is the same schedule used in patients with IPF. Participants and their doctors will not know which treatment they are getting until the end of the study, unless this needs to be revealed for safety reasons.

The main goal of this trial is to find out whether people with iSGS can stay on pirfenidone for one year, and how often they have moderate or more serious side effects compared with placebo. The study team will watch closely for side effects such as stomach upset, skin rash or sensitivity to sunlight, tiredness, and changes in liver blood tests. The study will also show whether a larger trial is possible, by measuring how many eligible patients agree to take part and how many complete the year of treatment. The team will also look for early signs that pirfenidone may help, such as a longer time until the next airway surgery, better breathing (peak flow) measurements, and improvements in breathlessness and voice related quality of life scores.

Forty four participants will take part at two hospitals, one in London and one in Toronto, Ontario. Each participant will be followed for up to two years: one year on study medication and one year of follow up after treatment. This study may not directly help every person who takes part, but the results will show whether pirfenidone is tolerable in iSGS and will provide the information needed to plan a larger trial testing whether it could become the first medication to slow this scarring airway disease.

Read the detailed description

Idiopathic subglottic stenosis (iSGS) is a progressive fibro-inflammatory airway disease characterized by recurrent scarring and narrowing of the subglottic and upper tracheal airway in otherwise healthy adults, predominantly women. Current management relies on repeated endoscopic dilations and serial intralesional steroid injections, which temporarily restore airway patency but are not curative and are associated with high rates of restenosis and substantial symptom burden. Molecular and single-cell transcriptomic studies from the Canadian Airways Research (CARE) Group biobank have demonstrated a fibrotic gene expression signature in iSGS, with transforming growth factor (TGF)-mediated fibroblast activation and extracellular matrix deposition that closely parallels idiopathic pulmonary fibrosis (IPF).

Pirfenidone is an oral antifibrotic agent approved for IPF that inhibits TGF-driven fibroblast proliferation, collagen synthesis, and profibrotic cytokine release and has an established long-term safety profile in chronic fibrotic lung disease. On this mechanistic basis, pirfenidone is being repurposed as a potential disease-modifying therapy for iSGS. This multicentre, randomized (1:1), double blinded, placebo controlled pilot trial will determine the tolerability of pirfenidone over 52 weeks and the feasibility of a placebo controlled trial in adults with iSGS receiving standardized intralesional steroid injections.

Hypothesis: Pirfenidone will be tolerable in iSGS, with no excess of adverse events beyond its established profile and at least 80% of participants still taking study drug at 52 weeks.

Forty four participants (22 per site) aged 18-65 years with a diagnosis of iSGS will be enrolled across two tertiary airway centres (London Health Sciences Centre - Victoria Hospital and St. Michael's Hospital, Unity Health Toronto). Participants will be randomized in a 1:1 ratio to receive oral pirfenidone or matching placebo for 52 weeks, in addition to protocolized intralesional steroid injections. Pirfenidone will be titrated from 801 mg/day in Week 1 to 1,602 mg/day in Week 2 and 2,403 mg/day (801 mg three times daily) from Week 3 onward, as tolerated. Study drug and placebo will be identical in appearance, and participants, investigators, and study staff will remain blinded to treatment allocation unless unblinding is required for safety.

The primary objective is to determine the tolerability of 52 weeks of pirfenidone treatment in iSGS. The primary endpoint is the proportion of participants who experience a moderate or worse (Grade ≥2, CTCAE v5.0) adverse event during 52 weeks of treatment. Tolerability is further described by the proportion still taking study drug at 52 weeks, rates of dose reduction, interruption and discontinuation, and protocol-defined laboratory abnormalities, particularly elevations in liver enzymes. Safety monitoring will include regular clinical assessments, vital signs, complete blood counts, renal function, and liver function tests at baseline, early after initiation, and at 3-month intervals. An independent Data Safety Monitoring Board will periodically review unblinded safety data under a signed charter and provide recommendations regarding trial continuation or modification.

Secondary and exploratory outcomes will characterize preliminary efficacy signals. These include time from randomization to first endoscopic dilation, total number of dilations during the 52-week treatment period, changes in peak expiratory flow, and patient-reported outcomes assessed using the Dyspnea Index and Voice Handicap Index-10 (VHI-10). Endoscopic laryngoscopic assessments will document airway patency and subglottic mucosal appearance over time, and may be correlated with clinical and functional outcomes.

Sample size: The primary endpoint is the proportion of participants who experience a moderate or worse (Grade ≥2) adverse event during 52 weeks of treatment. Assuming this occurs in 10% of placebo and 50% of pirfenidone recipients, 19 participants per arm provide 80% power to detect the difference (Fisher's exact test, one sided α = 0.05). A one sided test is used because the question is directional: whether pirfenidone increases moderate or worse adverse events relative to placebo. The primary analysis includes every participant who receives at least one dose of study drug, so later withdrawals do not reduce the analysis population, and enrolment of 22 per arm (N = 44) already exceeds the 19 per arm required. The 10% placebo assumption reflects events attributed to study drug rather than to the dilations and steroid injections that both arms receive. With 22 per arm, the proportion still taking study drug at 52 weeks will be estimated with a 95% confidence interval of approximately ±20 percentage points.

Statistical analysis: Reporting will follow the CONSORT extension for randomized pilot and feasibility trials. Tolerability and feasibility outcomes will be summarized by arm with exact (Clopper-Pearson) 95% confidence intervals and between arm risk differences. Consistent with pilot trial methodology, the trial is not powered for efficacy; clinical outcomes are exploratory and reported as estimates. Time to first dilation will be described using Kaplan-Meier estimates and a Cox proportional hazards model, reported as a hazard ratio with 95% confidence interval for planning a Phase III trial. Peak expiratory flow and patient reported outcomes will be analyzed with linear mixed effects models. Analyses of adverse events and dose maintenance will include all participants receiving at least one dose; clinical outcomes will be analyzed by intention to treat, including all randomized participants. Participants who withdraw are counted as no longer taking study drug, and missing repeated measures are handled within the mixed effects models under a missing at random assumption.

Concomitant medications will be managed to minimize interactions with pirfenidone, with exclusion of strong CYP1A2 inhibitors, CYP1A2 inducers such as smoking, and other antifibrotic agents. Participants will receive education on dosing with food, sun protection to reduce photosensitivity risk, adherence strategies, and timely reporting of side effects. Compliance will be assessed via pill counts, medication diaries, and scheduled visits every 3 months, supplemented with interim contact as needed.

This trial is designed to establish the tolerability of systemic antifibrotic therapy in iSGS and the feasibility of a placebo controlled trial, while generating early evidence on its potential to reduce procedure frequency and improve respiratory and voice-related quality of life. If tolerability is established, the results will inform the design of a large Phase III efficacy trial across the CARE network and may represent a critical step toward introducing the first disease-modifying pharmacologic therapy for this rare airway disorder.

02

Conditions studied

  • Idiopathic Subglottic Stenosis
  • Subglottic Stenosis (SGS)

Keywords

  • Subglottic Stenosis
  • Idiopathic Subglottic stenosis
  • Airway Fibrosis
  • Pirfenidone
03

In context

Lead sponsor

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's is the lead sponsor of 332 studies on the registry; 137 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

The criteria were revised on the registry on Nov 4, 2026. See what changed

Ages eligible
18 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adults 18-65 years of age
  • Confirmed diagnosis of idiopathic subglottic stenosis (iSGS)
  • At least 1 endoscopic dilation within the past 12 months, or receiving intralesional injections every 3 months as part of iSGS management
  • Clinically stable at enrollment (no acute infection or active inflammation)
  • Adequate liver and renal function on screening laboratory tests
  • Willing and able to comply with study procedures, visits, and follow-up
  • Ability to provide written
  • For participants of : negative pregnancy test and agreement to use effective during treatment and for the protocol-specified period after the last dose

Exclusion criteria

Exclusion Criteria:

  • Subglottic stenosis due to another identifiable cause (e.g., intubation, granulomatosis with polyangiitis, )
  • Known or allergic reaction to pirfenidone or any component of its formulation
  • Severe hepatic impairment or active liver disease ( or ALT above the )
  • Severe renal impairment or requirement for dialysis
  • Concurrent use of fluvoxamine
  • Use of high-dose ciprofloxacin or other strong CYP1A2 inhibitors where dose adjustment is not feasible
  • Current smoking or unwillingness to abstain from smoking during treatment
  • Pregnant or breastfeeding individuals
  • comorbid illness that could increase risk or confound results (e.g., advanced cardiac, pulmonary, or disease)
  • History of photosensitivity disorders or inability to adhere to sun protection precautions
  • Participation in another clinical trial within the previous 30 days
  • Any condition that, in the investigator's judgment, would interfere with safety monitoring, adherence, or study assessments
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Pirfenidone plus standardized intralesional steroid therapy

    Participants in this arm will receive oral pirfenidone in addition to standardized intralesional steroid injections for idiopathic subglottic stenosis. Pirfenidone will be titrated from 801 mg/day in Week 1 to 1,602 mg/day in Week 2, then to a maintenance dose of 2,403 mg/day (801 mg three times daily) from Week 3 through Week 52, as tolerated. Study drug will be taken with food to reduce gastrointestinal side effects. All participants will continue to receive protocolized intralesional steroid injections as part of their usual airway management. Participants will be followed during treatment and for an additional post-treatment follow-up period to assess safety, tolerability, and preliminary efficacy.

    Drug: Pirfenidone

  • Placebo comparator
    Placebo plus standardized intralesional steroid therapy

    Participants in this arm will receive an oral placebo in addition to standardized intralesional steroid injections for idiopathic subglottic stenosis. Placebo will be identical to pirfenidone in appearance, packaging and dosing schedule, including titration over the first 2 weeks and maintenance dosing three times daily with food through Week 52. All participants will continue to receive protocolized intralesional steroid injections as part of their usual airway management. Participants will be followed during treatment and for an additional post-treatment follow-up period to assess safety, tolerability, and to compare outcomes with the pirfenidone arm.

    Drug: Placebo

Interventions

  • Oral pirfenidone (267 mg units) given as systemic antifibrotic therapy for idiopathic subglottic stenosis. Participants assigned to the experimental arm will follow a standard titration regimen: 801 mg/day (267 mg three times daily) during Week 1, 1,602 mg/day (534 mg three times daily) during Week 2, and 2,403 mg/day (801 mg three times daily) from Week 3 through Week 52, as tolerated. Doses are taken with food to reduce gastrointestinal side effects. Pirfenidone is given in addition to standardized intralesional steroid injections as part of protocolized airway management.

  • DrugPlacebo

    Oral placebo identical to pirfenidone in appearance, packaging and dosing schedule. Participants assigned to the placebo comparator arm will receive placebo using the same titration and maintenance schedule as the pirfenidone arm (three times daily with food for 52 weeks). Placebo is given in addition to standardized intralesional steroid injections as part of protocolized airway management, to allow blinded comparison with active pirfenidone treatment.

06

What researchers measure

Primary outcomes

  1. Proportion of participants with a moderate or worse (Grade ≥2) adverse event

    Proportion of participants in each arm who experience at least one moderate or worse (Grade ≥2) adverse event during 52 weeks of treatment, graded using CTCAE v5.0 at every study visit. The analysis includes all participants who receive at least one dose of study drug, and results are reported by arm with exact 95% confidence intervals and the between arm risk difference.

    Time frame: From first dose of study drug through Week 52 of treatment

Secondary outcomes

  1. Time to first dilation

    Time from randomization to first endoscopic airway dilation performed for clinically significant recurrent subglottic stenosis, comparing pirfenidone with placebo.

    Time frame: From randomization through end of study follow-up, up to 24 months.

  2. Change in peak expiratory flow

    Change from baseline in peak expiratory flow (L/min), measured in clinic at scheduled study visits, comparing pirfenidone with placebo.

    Time frame: Baseline; Months 1, 3, 6, 9 and 12 of treatment

  3. Change in Dyspnea Index (DI) total score

    Change from baseline in the Dyspnea Index (DI), a 10 item patient reported measure of upper airway related breathlessness. Each item is scored 0 to 4, giving a total score from 0 to 40; higher scores indicate worse dyspnea. Compared between pirfenidone and placebo.

    Time frame: Baseline; Months 1, 3, 6, 9 and 12 of treatment; and Months 15, 18, 21 and 24 of follow up

  4. Change in Voice Handicap Index-10 (VHI-10) total score

    Change from baseline in the Voice Handicap Index-10 (VHI-10), a 10 item patient reported measure of voice related quality of life. Each item is scored 0 to 4, giving a total score from 0 to 40; higher scores indicate a greater voice handicap (worse outcome). Compared between pirfenidone and placebo.

    Time frame: Baseline; Months 1, 3, 6, 9 and 12 of treatment; and Months 15, 18, 21 and 24 of follow up

  5. Proportion of participants still taking study drug at Week 52

    Proportion of randomized participants in each arm still taking study drug at Week 52 (target ≥80% in the pirfenidone arm), with mean dose intensity and rates of dose reduction, interruption and discontinuation reported alongside. Participants who withdraw are counted as no longer taking study drug.

    Time frame: Week 52 of treatment

  6. Number of endoscopic dilations and intralesional steroid injections

    Total number of endoscopic airway dilations and intralesional steroid injections per participant during the 52 week treatment period, comparing pirfenidone with placebo.

    Time frame: From randomization through Week 52 of treatment

  7. Recruitment and retention

    Feasibility of a larger Phase III trial, measured by the number of participants randomized (target 44 by Month 11 of enrolment, from screening logs of eligible, approached, consented and randomized patients) and the proportion completing the Week 52 visit (target ≥85%).

    Time frame: Recruitment through Month 11 of enrolment; retention at Week 52 of treatment

07

Study locations

2 sites
  • Schulich School of Medicine and Dentistry / LHSCRI
    London, Ontario N6A 4L6, Canada
    • Halema Khan, PhD · Contacthalema.khan@lhsc.on.ca · 2267002100
    • Anthony C Nichols, MD · Principal investigator
    • Kevin Fung, MD · Sub investigator
  • St. Michael's Hospital, Unity Health Toronto
    Toronto, Ontario M5B 1W8, Canada
    • R. Jun Lin, MD, MSc · Principal investigator
08

References and documents

Publications

  • Ying S, Zeng PYF, Fung K, Khan H, Cecchini MJ, MacInnis P, Anderson J, Karimi AH, Al Jawhri M, Pan H, Le N, Joris K, Mymryk JS, Dumeaux V, Barrett JW, Nichols AC, Lin RJ; Canadian Airways Research Group of the Canadian Society of Otolaryngology Collaborative Research Initiative. Effect of Serial Intralesional Steroid Injections on Risk of Recurrence in Idiopathic Subglottic Stenosis. Laryngoscope. 2025 Sep;135(9):3265-3272. doi: 10.1002/lary.32179. Epub 2025 Apr 16. PubMed 40237535 ↗
  • Ying S, Zeng PYF, Fung K, Khan H, Cecchini MJ, Woo E, Anderson J, MacInnis P, Karimi AH, Al Jawhri M, Pan H, Le N, Joris K, Wen R, Mymryk JS, Inculet R, Dumeaux V, Barrett JW, Nichols AC, Lin RJ; Canadian Airways Research Group of the Canadian Society of Otolaryngology Collaborative Research Initiative. Transcriptomic Features of Recurrence Rates in Idiopathic Subglottic Stenosis. Laryngoscope. 2025 Sep;135(9):3273-3279. doi: 10.1002/lary.32214. Epub 2025 May 6. PubMed 40326273 ↗
  • Lin RJ, Zeng PYF, Fung K, Khan H, Cecchini MJ, Woo E, Hu A, Anderson J, MacInnis P, Karimi A, Ying S, Al Jawhri M, Lin S, Jarycki L, Shaikh MH, Pan H, Coburn B, Mymryk JS, Inculet R, Barrett JW, Nichols AC; Canadian Airways Research Group of the Canadian Society of Otolaryngology Collaborative Research Initiative. Cohort-level clinical trajectory and molecular landscape of idiopathic subglottic stenosis for precision laryngology-a study of the Canadian Airways Research (CARE) group. EBioMedicine. 2025 Apr;114:105629. doi: 10.1016/j.ebiom.2025.105629. Epub 2025 Mar 5. PubMed 40048847 ↗
  • Zeng PYF, Lin RJ, Fung K, Khan H, Cecchini MJ, Woo E, Hu A, Anderson J, MacInnis P, Jarycki L, Karimi A, Ying S, Al Jawhri M, Lin S, Shaikh M, Pan H, Coburn B, Mymryk JS, Inculet R, Barrett JW, Nichols AC; Canadian Airways Research Group of the Canadian Society of Otolaryngology Collaborative Research Initiative. Cellular blueprint of healthy and diseased human epiglottis and subglottis-a study of the Canadian Airways Research (CARE) group. EBioMedicine. 2025 Apr;114:105631. doi: 10.1016/j.ebiom.2025.105631. Epub 2025 Mar 5. PubMed 40048848 ↗
  • Brandenburg JH. Idiopathic subglottic stenosis. Trans Am Acad Ophthalmol Otolaryngol. 1972 Sep-Oct;76(5):1402-6. No abstract available. PubMed 4666597 ↗
  • Valdez TA, Shapshay SM. Idiopathic subglottic stenosis revisited. Ann Otol Rhinol Laryngol. 2002 Aug;111(8):690-5. doi: 10.1177/000348940211100806. PubMed 12184589 ↗
  • Aravena C, Almeida FA, Mukhopadhyay S, Ghosh S, Lorenz RR, Murthy SC, Mehta AC. Idiopathic subglottic stenosis: a review. J Thorac Dis. 2020 Mar;12(3):1100-1111. doi: 10.21037/jtd.2019.11.43. PubMed 32274178 ↗
  • Gelbard A, Donovan DT, Ongkasuwan J, Nouraei SA, Sandhu G, Benninger MS, Bryson PC, Lorenz RR, Tierney WS, Hillel AT, Gadkaree SK, Lott DG, Edell ES, Ekbom DC, Kasperbauer JL, Maldonado F, Schindler JS, Smith ME, Daniero JJ, Garrett CG, Netterville JL, Rickman OB, Sinard RJ, Wootten CT, Francis DO. Disease homogeneity and treatment heterogeneity in idiopathic subglottic stenosis. Laryngoscope. 2016 Jun;126(6):1390-6. doi: 10.1002/lary.25708. Epub 2015 Nov 4. PubMed 26536285 ↗
  • Maldonado F, Loiselle A, Depew ZS, Edell ES, Ekbom DC, Malinchoc M, Hagen CE, Alon E, Kasperbauer JL. Idiopathic subglottic stenosis: an evolving therapeutic algorithm. Laryngoscope. 2014 Feb;124(2):498-503. doi: 10.1002/lary.24287. Epub 2013 Aug 8. PubMed 23818139 ↗
  • Gelbard A, Anderson C, Berry LD, Amin MR, Benninger MS, Blumin JH, Bock JM, Bryson PC, Castellanos PF, Chen SC, Clary MS, Cohen SM, Crawley BK, Dailey SH, Daniero JJ, de Alarcon A, Donovan DT, Edell ES, Ekbom DC, Fernandes-Taylor S, Fink DS, Franco RA, Garrett CG, Guardiani EA, Hillel AT, Hoffman HT, Hogikyan ND, Howell RJ, Huang LC, Hussain LK, Johns MM 3rd, Kasperbauer JL, Khosla SM, Kinnard C, Kupfer RA, Langerman AJ, Lentz RJ, Lorenz RR, Lott DG, Lowery AS, Makani SS, Maldonado F, Mannion K, Matrka L, McWhorter AJ, Merati AL, Mori MC, Netterville JL, O'Dell K, Ongkasuwan J, Postma GN, Reder LS, Rohde SL, Richardson BE, Rickman OB, Rosen CA, Rutter MJ, Sandhu GS, Schindler JS, Schneider GT, Shah RN, Sikora AG, Sinard RJ, Smith ME, Smith LJ, Soliman AMS, Sveinsdottir S, Van Daele DJ, Veivers D, Verma SP, Weinberger PM, Weissbrod PA, Wootten CT, Shyr Y, Francis DO. Comparative Treatment Outcomes for Patients With Idiopathic Subglottic Stenosis. JAMA Otolaryngol Head Neck Surg. 2020 Jan 1;146(1):20-29. doi: 10.1001/jamaoto.2019.3022. PubMed 31670805 ↗
  • King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW; ASCEND Study Group. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014 May 29;370(22):2083-92. doi: 10.1056/NEJMoa1402582. Epub 2014 May 18. PubMed 24836312 ↗
  • Costabel U, Albera C, Lancaster LH, Lin CY, Hormel P, Hulter HN, Noble PW. An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP). Respiration. 2017;94(5):408-415. doi: 10.1159/000479976. Epub 2017 Sep 13. PubMed 28898890 ↗
  • Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM; CAPACITY Study Group. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011 May 21;377(9779):1760-9. doi: 10.1016/S0140-6736(11)60405-4. Epub 2011 May 13. PubMed 21571362 ↗
  • Lewis GA, Dodd S, Clayton D, Bedson E, Eccleson H, Schelbert EB, Naish JH, Jimenez BD, Williams SG, Cunnington C, Ahmed FZ, Cooper A, Rajavarma Viswesvaraiah, Russell S, McDonagh T, Williamson PR, Miller CA. Pirfenidone in heart failure with preserved ejection fraction: a randomized phase 2 trial. Nat Med. 2021 Aug;27(8):1477-1482. doi: 10.1038/s41591-021-01452-0. Epub 2021 Aug 12. PubMed 34385704 ↗
  • Stahnke T, Kowtharapu BS, Stachs O, Schmitz KP, Wurm J, Wree A, Guthoff RF, Hovakimyan M. Suppression of TGF-beta pathway by pirfenidone decreases extracellular matrix deposition in ocular fibroblasts in vitro. PLoS One. 2017 Feb 23;12(2):e0172592. doi: 10.1371/journal.pone.0172592. eCollection 2017. PubMed 28231275 ↗
  • Eldridge SM, Chan CL, Campbell MJ, Bond CM, Hopewell S, Thabane L, Lancaster GA; PAFS consensus group. CONSORT 2010 statement: extension to randomised pilot and feasibility trials. Pilot Feasibility Stud. 2016 Oct 21;2:64. doi: 10.1186/s40814-016-0105-8. eCollection 2016. PubMed 27965879 ↗
  • Thabane L, Ma J, Chu R, Cheng J, Ismaila A, Rios LP, Robson R, Thabane M, Giangregorio L, Goldsmith CH. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010 Jan 6;10:1. doi: 10.1186/1471-2288-10-1. PubMed 20053272 ↗
  • Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida JR, Bayley A, Goldstein DP, Hier M, Sultanem K, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo J, MacNeil SD, Winquist E, Hammond JA, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Chen J, Corsten M, Johnson-Obaseki S, Eapen L, Odell M, Parker C, Wehrli B, Kwan K, Palma DA. Radiotherapy versus transoral robotic surgery and neck dissection for oropharyngeal squamous cell carcinoma (ORATOR): an open-label, phase 2, randomised trial. Lancet Oncol. 2019 Oct;20(10):1349-1359. doi: 10.1016/S1470-2045(19)30410-3. Epub 2019 Aug 12. PubMed 31416685 ↗
  • Nichols AC, Theurer J, Prisman E, Read N, Berthelet E, Tran E, Fung K, de Almeida JR, Bayley A, Goldstein DP, Hier M, Sultanem K, Richardson K, Mlynarek A, Krishnan S, Le H, Yoo J, MacNeil SD, Winquist E, Hammond JA, Venkatesan V, Kuruvilla S, Warner A, Mitchell S, Chen J, Johnson-Obaseki S, Odell M, Corsten M, Parker C, Wehrli B, Kwan K, Palma DA. Radiotherapy Versus Transoral Robotic Surgery for Oropharyngeal Squamous Cell Carcinoma: Final Results of the ORATOR Randomized Trial. J Clin Oncol. 2024 Dec;42(34):4023-4028. doi: 10.1200/JCO.24.00119. Epub 2024 Sep 20. PubMed 39303189 ↗
  • Palma DA, Prisman E, Berthelet E, Tran E, Hamilton S, Wu J, Eskander A, Higgins K, Karam I, Poon I, Husain Z, Enepekides D, Hier M, Sultanem K, Richardson K, Mlynarek A, Johnson-Obaseki S, Odell M, Bayley A, Dowthwaite S, Jackson JE, Dzienis M, O'Neil J, Chandarana S, Banerjee R, Hart R, Chung J, Tenenholtz T, Krishnan S, Le H, Yoo J, Mendez A, Winquist E, Kuruvilla S, Stewart P, Warner A, Mitchell S, Chen J, Parker C, Wehrli B, Kwan K, Theurer J, Sathya J, Hammond JA, Read N, Venkatesan V, MacNeil SD, Fung K, Nichols AC. Assessment of Toxic Effects and Survival in Treatment Deescalation With Radiotherapy vs Transoral Surgery for HPV-Associated Oropharyngeal Squamous Cell Carcinoma: The ORATOR2 Phase 2 Randomized Clinical Trial. JAMA Oncol. 2022 Jun 1;8(6):1-7. doi: 10.1001/jamaoncol.2022.0615. PubMed 35482348 ↗
  • Julious SA. Sample size of 12 per group rule of thumb for a pilot study. Pharm Stat. 2005;4(4):287-291. doi: 10.1002/pst.185.

Individual participant data

Plan to share: Yes — De-identified individual participant data (IPD) underlying the main trial publications will be shared with qualified researchers upon reasonable request after completion of the study and publication of primary results. All datasets will be stripped of direct identifiers and prepared in accordance with applicable privacy regulations and institutional policies before sharing. Access will be granted only under a data use agreement that outlines the proposed research question, limits on data reuse and linkage, and requirements for data security and confidentiality.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Analytic code

Time frame: De-identified individual participant data (IPD) will be made available beginning approximately 12 months after completion of data collection for the primary outcome and publication of the main results, and will remain available for at least 5 years thereafter. The final study protocol, statistical analysis plan, and template informed consent form may be shared earlier, prior to completion of data analysis, to facilitate collaboration and potential participation of additional sites.

Access criteria: The protocol, statistical analysis plan, and template informed consent form may be shared with investigators at academic or healthcare institutions who express interest in collaboration or site participation, following institutional approvals and, where applicable, confidentiality agreements. After primary results are published, de-identified IPD and supporting documents will be available to qualified researchers with methodologically sound proposals that address scientifically valid questions. Requests should include a brief research proposal and data security plan and will be reviewed by the study team and institutional oversight as required. Approved requestors will sign a data use agreement specifying permitted uses, data security and confidentiality requirements, prohibition of re-identification, and conditions for publication and further sharing. Data and documents will be provided via secure, access-controlled electronic transfer or a trusted data repository.

Data sharing details ↗ · www.nicholslab.com

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Start is estimated for Apr 2027; primary completion for Mar 2029, 23 months later.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 4, 2026: start Dec 2026 → Apr 2027, primary completion Dec 2027 → Mar 2029 and completion Dec 2029 → Mar 2030.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 17, 2026
StartEst.
Apr 1, 2027was Dec 2026
Primary completionEst.
Mar 31, 2029was Dec 2027
CompletionEst.
Mar 31, 2030was Dec 2029
Last update
Nov 4, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added, 1 site removed
Show 2 added (2 Canada)
  • Schulich School of Medicine and Dentistry / LHSCRI · London, Canada
  • St. Michael's Hospital, Unity Health Toronto · Toronto, Canada
Show 1 removed
  • Schulich School of Medicine and Dentistry · London, Canada
Nov 4, 2026
Start date
Dec 1, 2026→Apr 1, 2027
Nov 4, 2026
Primary completion
Dec 1, 2027→Mar 31, 2029
Nov 4, 2026
Study completion
Dec 1, 2029→Mar 31, 2030
Nov 4, 2026
Enrollment
40→44
Nov 4, 2026
Eligibility
Maximum age none→65 Years; 1 inclusion criterion edited
What changed in the criteria
Inclusion criteria
  • EditedHistory of atAt least 21 endoscopic dilationsdilation within the past 12 months, or -Receiving regularreceiving intralesional steroid injections every 3 months as part of iSGS management (every 3 months)
Nov 4, 2026
Interventions
Changed Pirfenidone 267 MG [Esbriet]→Pirfenidone
Nov 4, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Incidence and severity of treatment-emergent adverse events over 52 weeksNow Proportion of participants with a moderate or worse (Grade ≥2) adverse eventTime frame: From first dose of study through week 52 of treatment. → From first dose of study drug through Week 52 of treatment
Nov 4, 2026
Secondary outcomes
2 edited, 1 time frame changed, 3 added, 1 description edited
What changed in the outcomes
  • EditedChange in Dyspnea Index Score(DI) total scoreTime frame: Baseline and approximately every 3 months during the 52-week treatment and every followup appointment during the second year. → Baseline; Months 1, 3, 6, 9 and 12 of treatment; and Months 15, 18, 21 and 24 of follow up
  • EditedChange in Voice Handicap Index-10 (VHI-10) total scoreTime frame: Baseline and approximately every 3 months during the 52-week treatment period and every follow up appointment during the followup period in the second year. → Baseline; Months 1, 3, 6, 9 and 12 of treatment; and Months 15, 18, 21 and 24 of follow up
  • AddedProportion of participants still taking study drug at Week 52Time frame: Week 52 of treatment
  • AddedNumber of endoscopic dilations and intralesional steroid injectionsTime frame: From randomization through Week 52 of treatment
  • AddedRecruitment and retentionTime frame: Recruitment through Month 11 of enrolment; retention at Week 52 of treatment
  • Time frameChange in peak expiratory flowBaseline and approximately every 3 months during the 52 week treatment period. → Baseline; Months 1, 3, 6, 9 and 12 of treatment
  • DescriptionChange in peak expiratory flow: how it is measured was reworded
Nov 4, 2026
Contact
Study contact changed: a•••@lhsc.on.ca · •••8500→a•••@lhsc.on.ca · •••8500. See the current contact
Nov 4, 2026
Title
A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis→Pirfenidone for Idiopathic Subglottic Stenosis: A Pilot Trial of Tolerability and Feasibility
Nov 4, 2026
Show all 1 update
  1. Nov 4, 2026
    2 sites added, 1 site removed
    Show 2 added (2 Canada)
    • Schulich School of Medicine and Dentistry / LHSCRI · London, Canada
    • St. Michael's Hospital, Unity Health Toronto · Toronto, Canada
    Show 1 removed
    • Schulich School of Medicine and Dentistry · London, Canada
    Start date Dec 1, 2026→Apr 1, 2027
    Primary completion Dec 1, 2027→Mar 31, 2029
    Study completion Dec 1, 2029→Mar 31, 2030
    Enrollment 40→44
    Eligibility Maximum age none→65 Years; 1 inclusion criterion edited
    What changed in the criteria
    Inclusion criteria
    • EditedHistory of atAt least 21 endoscopic dilationsdilation within the past 12 months, or -Receiving regularreceiving intralesional steroid injections every 3 months as part of iSGS management (every 3 months)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Incidence and severity of treatment-emergent adverse events over 52 weeksNow Proportion of participants with a moderate or worse (Grade ≥2) adverse eventTime frame: From first dose of study through week 52 of treatment. → From first dose of study drug through Week 52 of treatment
    Secondary outcomes 2 edited, 1 time frame changed, 3 added, 1 description edited
    What changed in the outcomes
    • EditedChange in Dyspnea Index Score(DI) total scoreTime frame: Baseline and approximately every 3 months during the 52-week treatment and every followup appointment during the second year. → Baseline; Months 1, 3, 6, 9 and 12 of treatment; and Months 15, 18, 21 and 24 of follow up
    • EditedChange in Voice Handicap Index-10 (VHI-10) total scoreTime frame: Baseline and approximately every 3 months during the 52-week treatment period and every follow up appointment during the followup period in the second year. → Baseline; Months 1, 3, 6, 9 and 12 of treatment; and Months 15, 18, 21 and 24 of follow up
    • AddedProportion of participants still taking study drug at Week 52Time frame: Week 52 of treatment
    • AddedNumber of endoscopic dilations and intralesional steroid injectionsTime frame: From randomization through Week 52 of treatment
    • AddedRecruitment and retentionTime frame: Recruitment through Month 11 of enrolment; retention at Week 52 of treatment
    • Time frameChange in peak expiratory flowBaseline and approximately every 3 months during the 52 week treatment period. → Baseline; Months 1, 3, 6, 9 and 12 of treatment
    • DescriptionChange in peak expiratory flow: how it is measured was reworded
    Interventions Changed Pirfenidone 267 MG [Esbriet]→Pirfenidone
    Contact Study contact changed: a•••@lhsc.on.ca · •••8500→a•••@lhsc.on.ca · •••8500. See the current contact
    Title A Phase I Evaluation of the Safety and Tolerability of Pirfenidone in Idiopathic Subglottic Stenosis→Pirfenidone for Idiopathic Subglottic Stenosis: A Pilot Trial of Tolerability and Feasibility
    + 4 other changes: verification date, description, design details and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07654517
Responsible party
Anthony Nichols (Professor, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's) — Principal investigator
First posted
Jun 17, 2026
Start date
Apr 1, 2027 (estimated)
Primary completion
Mar 31, 2029 (estimated)
Completion
Mar 31, 2030 (estimated)
Last update
Nov 4, 2026

Study contacts

Halema Khan, PhD
Contact
halema.khan@lhsc.on.ca
519-685-8500
Anthony Nichols, MD
Contact
anthony.nichols@lhsc.on.ca
519-685-8500 ext. 58804
Anthony C Nichols, MD
principal investigator · London Health Sciences Centre Research Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pirfenidone

Start the discussion